Phaseline

Companies › Electra Therapeutics

Electra Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Hematology, Oncology; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ELA026
SIRP-directed monoclonal antibody
SIRPAPhase 2Secondary Hemophagocytic Lymphohistiocytosis (sHLH); T Cell MalignanciesMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05416307ELA026Phase 2Secondary Hemophagocytic Lymphohistiocytosis (sHLH)HematologyMar 2028
NCT07465835ELA026Phase 1T Cell MalignanciesOncologyJun 2028

From the company's SEC filings

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Targets

SIRPA (1)

Companies with the same targets

FBD Biologics Sairopa Kahr Medical Byondis

Companies built like this

Syntrix Biosystems Theravia Servier Affaires Médicales NanoEcho Syncromune

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.